BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Holdings Lifted by Amalgamated Bank

Amalgamated Bank increased its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 792.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 95,922 shares of the biotechnology company's stock after purchasing an additional 85,177 shares during the quarter. Amalgamated Bank owned 0.05% of BioMarin Pharmaceutical worth $7,897,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in BMRN. Innealta Capital LLC purchased a new stake in BioMarin Pharmaceutical during the 2nd quarter worth approximately $25,000. BOKF NA acquired a new stake in BioMarin Pharmaceutical in the second quarter valued at $31,000. Quent Capital LLC boosted its stake in BioMarin Pharmaceutical by 58.9% during the 2nd quarter. Quent Capital LLC now owns 391 shares of the biotechnology company's stock valued at $32,000 after acquiring an additional 145 shares during the last quarter. Jones Financial Companies Lllp acquired a new position in BioMarin Pharmaceutical during the 4th quarter worth $43,000. Finally, AM Squared Ltd bought a new stake in shares of BioMarin Pharmaceutical in the 2nd quarter worth about $66,000. 98.71% of the stock is owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Stock Performance

Shares of BMRN traded down $0.72 during trading hours on Friday, reaching $70.69. 3,398,022 shares of the company's stock traded hands, compared to its average volume of 1,916,588. BioMarin Pharmaceutical Inc. has a twelve month low of $68.83 and a twelve month high of $99.56. The business's fifty day simple moving average is $85.57 and its two-hundred day simple moving average is $84.29. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.05 and a quick ratio of 1.95. The firm has a market capitalization of $13.42 billion, a price-to-earnings ratio of 66.07, a P/E/G ratio of 1.03 and a beta of 0.32.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last released its earnings results on Monday, August 5th. The biotechnology company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.38 by $0.39. The firm had revenue of $712.03 million for the quarter, compared to analysts' expectations of $660.51 million. BioMarin Pharmaceutical had a net margin of 9.91% and a return on equity of 6.91%. Analysts predict that BioMarin Pharmaceutical Inc. will post 2.4 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Piper Sandler increased their price target on shares of BioMarin Pharmaceutical from $107.00 to $122.00 and gave the stock an "overweight" rating in a research report on Thursday, September 5th. Truist Financial reduced their target price on BioMarin Pharmaceutical from $118.00 to $90.00 and set a "buy" rating on the stock in a report on Tuesday. Scotiabank lowered their price target on BioMarin Pharmaceutical from $95.00 to $78.00 and set a "sector perform" rating for the company in a report on Tuesday. William Blair raised BioMarin Pharmaceutical to a "strong-buy" rating in a research report on Friday, August 30th. Finally, Canaccord Genuity Group reaffirmed a "hold" rating and issued a $93.00 price objective on shares of BioMarin Pharmaceutical in a report on Friday, September 13th. Eight research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $98.84.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.